Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity

[1]  N. Petrovsky,et al.  Adjuvant selection impacts the correlates of vaccine protection against Ebola infection. , 2020, Vaccine.

[2]  Gengfu Xiao,et al.  Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus , 2019, Antiviral Research.

[3]  J. Armengaud,et al.  Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot , 2019, Science Translational Medicine.

[4]  S. Gilbert,et al.  Vaccine platforms for the prevention of Lassa fever , 2019, Immunology Letters.

[5]  R. Diskin,et al.  Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses , 2019, Journal of Virology.

[6]  M. A. Suchard,et al.  Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak , 2019, Science.

[7]  G. Gao,et al.  Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease , 2018, Journal of Virology.

[8]  Catherine A. Freije,et al.  Genomic analysis of Lassa virus from the 2018 surge in Nigeria , 2018, The New England journal of medicine.

[9]  P. Jahrling,et al.  Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever , 2018, Nature Communications.

[10]  G. Sutter,et al.  Generation of therapeutic antisera for emerging viral infections , 2018, npj Vaccines.

[11]  P. Millett,et al.  The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts , 2018, Antiviral Research.

[12]  D. Burton,et al.  Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization , 2018, Immunity.

[13]  Thomas Strecker,et al.  Structure of the Lassa virus glycan shield provides a model for immunological resistance , 2018, Proceedings of the National Academy of Sciences.

[14]  C. Picard,et al.  A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins , 2018, Journal of Virology.

[15]  B. R. Noack,et al.  New Lineage of Lassa Virus, Togo, 2016 , 2018, Emerging infectious diseases.

[16]  J. Hubbell,et al.  Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. , 2017, Virology.

[17]  N. Sardesai,et al.  A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever , 2017, Human vaccines & immunotherapeutics.

[18]  J. Galarza,et al.  Adjuvant formulations for virus-like particle (VLP) based vaccines. , 2017, Clinical immunology.

[19]  Donald S. Grant,et al.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.

[20]  R. Hewson,et al.  Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product , 2017, Scientific Reports.

[21]  K. Chandran,et al.  Structural basis for antibody-mediated neutralization of Lassa virus , 2017, Science.

[22]  S. K. Fehling,et al.  Genome Sequence of Lassa Virus Isolated from the First Domestically Acquired Case in Germany , 2016, Genome Announcements.

[23]  A. Tarr,et al.  Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay , 2016, The Journal of general virology.

[24]  Donald S. Grant,et al.  Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. , 2016, Antiviral research.

[25]  Zhìhóng Hú,et al.  Virus like particle-based vaccines against emerging infectious disease viruses , 2016, Virologica Sinica.

[26]  Pardis C Sabeti,et al.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits , 2016, Nature Communications.

[27]  S. Günther,et al.  New Hosts of The Lassa Virus , 2016, Scientific Reports.

[28]  G. Gao,et al.  Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection , 2016, Scientific Reports.

[29]  Thomas Strecker,et al.  Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike , 2016, PLoS pathogens.

[30]  Paolo Meda,et al.  Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection , 2015, PLoS pathogens.

[31]  N. Forrester,et al.  Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage , 2015, Front. Microbiol..

[32]  Timothy K. Soh,et al.  Lassa virus entry requires a trigger-induced receptor switch , 2014, Science.

[33]  S. Günther,et al.  Infection of Type I Interferon Receptor-Deficient Mice with Various Old World Arenaviruses: A Model for Studying Virulence and Host Species Barriers , 2013, PloS one.

[34]  A. Varki,et al.  Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation , 2012, Biotechnology & genetic engineering reviews.

[35]  J. York,et al.  The Curious Case of Arenavirus Entry, and Its Inhibition , 2012, Viruses.

[36]  Y. Kawaoka,et al.  Identification of Cell Surface Molecules Involved in Dystroglycan-Independent Lassa Virus Cell Entry , 2011, Journal of Virology.

[37]  M. Buchmeier,et al.  Glycosylation modulates arenavirus glycoprotein expression and function. , 2011, Virology.

[38]  K. Schlie,et al.  Maturation cleavage within the ectodomain of Lassa virus glycoprotein relies on stabilization by the cytoplasmic tail , 2010, FEBS letters.

[39]  F. J. Geske,et al.  Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever , 2010, Virology Journal.

[40]  K. Schlie,et al.  Viral Protein Determinants of Lassa Virus Entry and Release from Polarized Epithelial Cells , 2010, Journal of Virology.

[41]  Marc Daigneault,et al.  The Identification of Markers of Macrophage Differentiation in PMA-Stimulated THP-1 Cells and Monocyte-Derived Macrophages , 2010, PloS one.

[42]  K. Schlie,et al.  Characterization of Lassa Virus Glycoprotein Oligomerization and Influence of Cholesterol on Virus Replication , 2009, Journal of Virology.

[43]  H. Klenk,et al.  Inhibition of Lassa Virus Glycoprotein Cleavage and Multicycle Replication by Site 1 Protease-Adapted α1-Antitrypsin Variants , 2009, PLoS neglected tropical diseases.

[44]  R. Compans,et al.  Protection against lethal challenge by Ebola virus-like particles produced in insect cells. , 2009, Virology.

[45]  H. Klenk,et al.  Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity. , 2007, The Journal of general virology.

[46]  David A. Anderson,et al.  Virus-like particles: Passport to immune recognition , 2006, Methods.

[47]  W. Garten,et al.  The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C , 2006, Virology Journal.

[48]  V. Deubel,et al.  A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. , 2006, Virology.

[49]  I. Lukashevich,et al.  A Live Attenuated Vaccine for Lassa Fever Made by Reassortment of Lassa and Mopeia Viruses , 2005, Journal of Virology.

[50]  J. York,et al.  Genetic analysis of heptad-repeat regions in the G2 fusion subunit of the Junín arenavirus envelope glycoprotein , 2005, Virology.

[51]  B. Mothé,et al.  Development of a New Vaccine for the Prevention of Lassa Fever , 2005, PLoS medicine.

[52]  M. Buchmeier,et al.  Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. , 2005, Virology.

[53]  J. Auwerx,et al.  The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation , 1991, Experientia.

[54]  M. Aman,et al.  Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. , 2004, Vaccine.

[55]  H. Feldmann,et al.  Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.

[56]  M. Georges-Courbot,et al.  Lassa Virus Infection of Human Dendritic Cells and Macrophages Is Productive but Fails to Activate Cells1 , 2004, The Journal of Immunology.

[57]  M. Mohamadzadeh,et al.  Ebola virus-like particles protect from lethal Ebola virus infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  W. Weissenhorn,et al.  Lassa Virus Z Protein Is a Matrix Protein and Sufficient for the Release of Virus-Like Particles , 2003, Journal of Virology.

[59]  W. Garten,et al.  Signal peptide of Lassa virus glycoprotein GP‐C exhibits an unusual length , 2003, FEBS letters.

[60]  W. Garten,et al.  Endoproteolytic Processing of the Lymphocytic Choriomeningitis Virus Glycoprotein by the Subtilase SKI-1/S1P , 2003, Journal of Virology.

[61]  N. Seidah,et al.  The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  H. Feldmann,et al.  Identification of a Novel Consensus Sequence at the Cleavage Site of the Lassa Virus Glycoprotein , 2000, Journal of Virology.

[63]  L. Hutwagner,et al.  Effective Vaccine for Lassa Fever , 2000, Journal of Virology.

[64]  Stuart T. Nichol,et al.  Genetic Diversity among Lassa Virus Strains , 2000, Journal of Virology.

[65]  K. Campbell,et al.  Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. , 1998, Science.

[66]  J. McCormick,et al.  Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys , 1992, Journal of medical virology.

[67]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[68]  M. Buchmeier,et al.  Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus , 1990, Virology.

[69]  L. Brammer,et al.  Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. B. McCormick,et al.  A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. , 1988, BMJ.

[71]  E. S. Smith,et al.  A prospective study of the epidemiology and ecology of Lassa fever. , 1987, The Journal of infectious diseases.

[72]  J. McCormick.  Epidemiology and control of Lassa fever. , 1987, Current topics in microbiology and immunology.

[73]  J. McCormick,et al.  Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. , 1986, Virology.

[74]  J. McCormick,et al.  Lassa fever. Effective therapy with ribavirin. , 1986, The New England journal of medicine.

[75]  P. Jahrling,et al.  Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. , 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[76]  P. Jahrling,et al.  Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain , 1984, Infection and immunity.

[77]  P. Jahrling,et al.  Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. , 1984, The Journal of infectious diseases.

[78]  J. Frame,et al.  The use of Lassa fever convalescent plasma in Nigeria. , 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[79]  P. Jahrling.  Protection of lassa virus‐infected guinea pigs with lassa‐immune plasma of guinea pig, primate, and human origin , 1983, Journal of medical virology.